ftInvstr
WINDLAS · Healthcare ₹972.0 -4.56% Mkt Cap ₹2008 Cr

WINDLAS

Healthcare Drug Manufacturers - Specialty & Generic
₹972.0
-4.56% today · 30d +1.9%
as of 2026-11-09
Price · Daily Candles
“Windlas Biotech's quarterly profits dip amidst strong revenue growth, FIIs increase stake.”
Windlas Biotech (WINDLAS) reported Q4FY26 revenue growth of +17.66% YoY to ₹238 Cr, yet net profit declined by -1.79% YoY to ₹16 Cr. Annually, revenue grew +18.98% to ₹904 Cr with 3-year revenue CAGR at 20.01%. Despite this, the company faces weak FCF growth predictions.
BULL CASE
+Q4FY26 revenue increased +17.66% YoY to ₹238 Cr, and annual revenue grew +18.98% YoY to ₹904 Cr.
+The company's 3-year revenue CAGR stands at 20.01% as of FY26.
+FIIs increased their stake by 0.39% QoQ, holding 0.99% as of May 18, 2026.
+The stock is trading at a PE of 26.2, lower than sector leaders like DIVISLAB (69.81) and SUNPHARMA (40.41).
BEAR CASE
−Q4FY26 net profit declined -1.79% YoY to ₹16 Cr, with operating profit also down -2.79% YoY.
−Operating Profit Margin (OPM) saw a -2.48% change QoQ in Q4FY26.
−DIIs decreased their stake by -1.61% QoQ, holding 10.2% as of May 18, 2026.
−ML models predict weak Free Cash Flow (FCF) growth, with ranks for FCF growth being below 0.1 for all lookback periods.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹238 Cr
+17.66% YoY
NET PROFIT
₹16 Cr
-1.79% YoY
OPM
12.2%
-2.48pp YoY
EPS
₹7.58
PE 26.2
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-0.8%, h2=-1.3%, h3=-1.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
WINDLAS, with a PE of 26.2 and ROCE of 17.0%, trades at a significantly lower valuation than sector behemoths like DIVISLAB (PE 69.81, ROCE 21.47%) and SUNPHARMA (PE 40.41, ROCE 22.46%).
PEERPEROCE %
WINDLAS26.217.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
63
SCORE / 100
Overall
6-axis composite of the sections below.
Performance POSITIVE 55
Valuation REASONABLE 60
Growth STEADY 60
Profitability DECENT 68
Technicals NEUTRAL 67
Risk LOW 70
Key Stats
TTM PE
26.2
P/B
3.23
52W HIGH
₹1181.9
OFF HIGH
-17.76%
DIV YIELD
0.74%
MKT CAP
₹2008 Cr
◉ Active Signals
MACDNeutral17.0704
RSI(14)Neutral53.09
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold WINDLAS and at what entry.

Sign up freeSign in